The concept of the Cambridge Biomedical Campus was formed in 1999 by Addenbrooke’s Hospital, the landowner of the site south-east of Cambridge.

The site was already a hub of research, education and patient care but Addenbrooke’s formed a plan – called the 2020 Vision – to transform it into a world-leading biomedical centre to attract leading commercial organisations in the research and biomedical fields. Bidwells have advised since the beginning.

Liberty Property Trust and Countryside Properties were brought in as developers for the 3.1 million sq ft scheme. In 2010, the Medical Research Council signed a deal to house its Laboratory of Molecular Biology in a new 330,000 sq ft facility on the site – providing the scope to develop the infrastructure for the rest of the Campus.

But it was the choice of international biomedical research and pharmaceutical company, AstraZeneca, to relocate its global HQ to a 875,000 sq ft site on the Campus that was the game changer for this project. Addenbrooke’s 2020 Vision has already become a reality.

Our clients always had the vision of the Campus as a world-leading biomedical centre rather than a conventional science park. The Cambridge Biomedical Campus offers unrivalled facilities in a specially designed environment to enable companies to flourish in this fast-growing sector. Will Heigham, Partner